Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
Authors:
Open Access
- 26 August 2023
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 80 (23) , 1708-1721
Abstract
Purpose: This review provides an overview of the management of chronic kidney disease (CKD) associated with type 2 diabetes (T2D), how the novel treatment class of nonsteroidal mineralocorticoid receptor antagonists (MRAs) fits within the treatment landscape, and how pharmacists can contribute to the multidisciplinary care of patients with CKD associated with T2D. Summary: Optimizing pharmacotherapy for patients with CKD associated with T2D is critical to prevent or slow progression to end-stage kidney disease and reduce the incidence of cardiovascular events. However, many patients with CKD receive suboptimal treatment, in part because of the high complexity of care required, a lack of disease recognition among providers and patients, and a failure to utilize new kidney-protective therapies. Finerenone is the first nonsteroidal, selective MRA to be approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of adult patients with CKD associated with T2D. Clinical trials have demonstrated that finerenone significantly reduces the risk of cardiorenal disease progression vs placebo and has a reduced risk of hyperkalemia compared to traditional steroidal MRAs. Initiation of finerenone should follow evaluation of baseline estimated glomerular filtration rate and serum potassium levels. Consideration of potential drug-drug interactions, follow-up monitoring of potassium levels, and coordination of changes in pharmacotherapy across the patient care team are also important. Conclusion: Finerenone is a valuable addition to the treatment landscape for CKD associated with T2D. Through their expertise in medication management, transitions of care, and patient education, clinical pharmacists are well positioned to ensure patients receive safe and effective treatment.Keywords
This publication has 42 references indexed in Scilit:
- Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European studyEuropean Heart Journal, 2017
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney diseaseEuropean Heart Journal, 2016
- Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012BMJ Open Diabetes Research & Care, 2016
- Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone – results from first‐in‐man and relative bioavailability studiesFundamental & Clinical Pharmacology, 2016
- Patient Benefits And Cost Savings Predicted For Mineralocorticoid-Receptor Antagonist Treatment Of Early And Advanced Diabetic Kidney DiseaseValue in Health, 2015
- Effect of Finerenone on Albuminuria in Patients With Diabetic NephropathyJAMA, 2015
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal InjuryJournal of Cardiovascular Pharmacology, 2014
- New models of chronic kidney disease care including pharmacistsCurrent Opinion in Nephrology and Hypertension, 2013
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trialEuropean Heart Journal, 2013
- Rationale and Design of ARTS: A Randomized, Double-Blind Study of BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney DiseaseEuropean Journal of Heart Failure, 2012